Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation
Andrew P Demidowich1, Angela I Davis1, Nicket Dedhia1
1Section on Growth and Obesity, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, DHHS, United States.
Abstract:
Obesity is a major risk-factor for the development of insulin resistance, type 2 diabetes, and cardiovascular disease. Circulating molecules associated with obesity, such as saturated fatty acids and cholesterol crystals, stimulate the innate immune system to incite a chronic inflammatory state. Studies in mouse models suggest that suppressing the obesity-induced chronic inflammatory state may prevent or reverse obesity-associated metabolic dysregulation. Human studies, however, have been far less positive, possibly because targeted interventions were too far downstream of the inciting inflammatory events. Recently, it has been shown that, within adipose tissue macrophages, assembly of a multi-protein member of the innate immune system, the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, is essential for the induction of this inflammatory state. Microtubules enable the necessary spatial arrangement of the components of the NLRP3 inflammasome in the cell, leading to its activation and propagation of the inflammatory cascade. Colchicine, a medication classically used for gout, mediates its anti-inflammatory effect by inhibiting tubulin polymerization, and has been shown to attenuate macrophage NLRP3 inflammasome arrangement and activation in vitro and in vivo. Given these findings, we hypothesize that, in at-risk individuals (those with obesity-induced inflammation and metabolic dysregulation), long-term colchicine use will lead to suppression of inflammation and thus cause improvements in insulin sensitivity and other obesity-related metabolic impairments.
Insights
Colchicine may improve metabolic health in obesity by targeting the NLRP3 inflammasome, a key driver of chronic inflammation. This study hypothesizes long-term use will reduce inflammation and improve insulin sensitivity in at-risk individuals.
Area of Science:
- Immunology
- Metabolic Disease
- Pharmacology
Background:
- Obesity triggers chronic inflammation via innate immune system activation, contributing to insulin resistance and cardiovascular disease.
- The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome in adipose tissue macrophages is crucial for obesity-induced inflammation.
- Microtubules are essential for NLRP3 inflammasome assembly and activation, propagating inflammatory cascades.
Purpose of the Study:
- To investigate the potential of long-term colchicine use to suppress obesity-induced inflammation.
- To determine if colchicine improves insulin sensitivity and other metabolic impairments associated with obesity.
- To explore colchicine's mechanism of action by assessing its effect on NLRP3 inflammasome activation.
Main Methods:
- Utilizing mouse models and in vitro studies to examine colchicine's effect on tubulin polymerization and NLRP3 inflammasome activation.
- Assessing the impact of colchicine on macrophage inflammatory responses.
- Proposing a hypothesis for human studies involving at-risk individuals with obesity-induced inflammation.
Main Results:
- Colchicine inhibits tubulin polymerization, a key step in NLRP3 inflammasome assembly.
- Colchicine attenuates NLRP3 inflammasome activation in macrophages both in vitro and in vivo.
- Mouse studies suggest suppressing obesity-induced inflammation may reverse metabolic dysregulation.
Conclusions:
- Colchicine's anti-inflammatory properties, mediated by microtubule inhibition, present a potential therapeutic strategy.
- Targeting the NLRP3 inflammasome with colchicine could offer a novel approach to managing obesity-related metabolic complications.
- Further human studies are warranted to confirm the efficacy of long-term colchicine use in improving metabolic health in at-risk populations.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:10Drugs that Destabilize Microtubules
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents